Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widder’s departure was part of an executive succession plan
Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widders departure was part of an executive succession plan that the company has been considering for some time. MBI has not named Widders replacement.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.